Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Huang, Ya Kai ^a   Yu, Jian Chun ^a   Kang, Wei Ming ^a   Ma, Zhi Qiang ^a   Ye, Xin ^a   Tian, Shu Bo ^a   Yan, Chao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN; BIOLOGICAL MARKER;

ARTICLE; ATROPHIC GASTRITIS; BLOOD SAMPLING; CHEMILUMINESCENCE IMMUNOASSAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC LIKELIHOOD RATIO; DIAGNOSTIC ODDS RATIO; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LATEX ENHANCED TURBIDIMETRIC IMMUNOASSAY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SYSTEMATIC REVIEW; BLOOD; EARLY CANCER DIAGNOSIS; GASTRITIS, ATROPHIC; META ANALYSIS; STOMACH NEOPLASMS;

BIOMARKERS; EARLY DETECTION OF CANCER; GASTRITIS, ATROPHIC; HUMANS; PEPSINOGENS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 84954071251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142080     Document Type: Article

References (68)

1. Wang K, Liang Q, Li X, Tsoi H, Zhang J, Wang H, et al. MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome. Gut. 2015. doi: 10.1136/ gutjnl-2015-309276
2. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2004; 7(1):9-16. doi: 10.1007/s10120-003-0265-0
3. Liu D, Zhang L, Shen Z, Tan F, Hu Y, Yu J, et al. Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2013; 16(4):498-504. doi: 10.1007/s10120-013-0232-3
4. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(12):2282-7. doi: 10.1200/JCO.2003.06.103
5. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World journal of gastroenterology: WJG. 2014; 20(38):13842-62. doi: 10.3748/wjg. v20.i38.13842
6. Shikata K, Ninomiya T, Yonemoto K, Ikeda F, Hata J, Doi Y, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scandinavian journal of gastroenterology. 2012; 47(6):669-75. doi: 10.3109/00365521.2012.658855
7. Choi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc. 2014; 47(6):497-503. doi: 10.5946/ce.2014.47.6.497
8. Samloff IM. Immunologic studies of human group I pepsinogens. Journal of immunology. 1971; 106 (4):962-8.
9. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Shakeri R, Persson EC, Islami F, et al. Accuracy and cutoff values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PloS one. 2011; 6(10):e26957. doi: 10.1371/journal.pone.0026957
10. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007; 8(1):8-14. doi: 10.1111/j.1443-9573.2007.00278.x PMID: WOS:000256831800002
11. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982; 83(1 Pt 2):204-9. Epub 1982/07/01.
12. Graham DY, Nurgalieva ZZ, El-Zimaity HM, Opekun AR, Campos A, Guerrero L, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006; 4(3):306-14. doi: 10.1016/j.cgh.2005.11.003
13. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52(24):6735-
14. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007; 46(6):261-6.
15. Zeng Z, Fu S, Hu P, Zhao L, Zhang H, Tang X, et al. The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis. Clinical and experimental medicine. 2014; 14 (3):337-43. doi: 10.1007/s10238-013-0246-5
16. Du Y, Li J, He F, Lv Y, Liu W, Wu P, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PloS one. 2014; 9(8):e104936. doi: 10.1371/ journal.pone.0104936
17. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC medical research methodology. 2011; 11:41. doi: 10.1186/1471-2288-11-41
18. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC medical research methodology. 2006; 6:31. doi: 10.1186/1471-2288-6-31
19. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999; 44(5):693-7. Epub 1999/04/16.
20. Nomura AM, Kolonel LN, Miki K, Stemmermann GN, Wilkens LR, Goodman MT, et al. Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. The Journal of infectious diseases. 2005; 191(12):2075-81. doi: 10.1086/430353
21. Haneda M, Kato M, Ishigaki S, Suzuki M, Takahashi M, Nakagawa M, et al. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori. Journal of gastroenterology and hepatology. 2013; 28(1):78-83. Epub 2012/10/05. doi: 10.1111/j.1440- 1746.2012.07285.x
22. Kikuchi R, Abe Y, Iijima K, Koike T, Ara N, Uno K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. The Tohoku journal of experimental medicine. 2011; 223(1):35-44.
23. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. European journal of gastroenterology & hepatology. 2012; 24(1):37-41. doi: 10.1097/MEG.0b013e32834d0a0a
24. Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2008; 13(2):146-56. doi: 10.1111/j.1523- 5378.2008.00592.x
25. Zhang XM, Li JX, Zhang GY, Li XH, Gu H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC gastroenterology. 2014; 14:3. Epub 2014/01/05. doi: 10.1186/1471-230x-14-3
26. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2009; 12 (3):158-63. Epub 2009/11/06. doi: 10.1007/s10120-009-0522-y
27. Huang YY, Cheng WC, Gao N, Ye N, Qian YT. The diagnostic value of serum pepsinogen ?, ? for gastric cancer and precancerous lesions of gastric cancer detection. Chinese Journal of Internal Medicine. 2013; 52(4):332-3. doi: 10.3760/cma.j.issn.0578-1426.2013.04.017
28. Yu ZL, Ji M, Yang X, Zhang PT, Huang XJ, Zhang ZY, et al. Serum pepsinogen detection in gastric cancer screening. Chinese journal of digestive endoscopy. 2008; 25(10):512-5. doi: 10.3760/cma.j.issn. 1007-5232.2008.10.003
29. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol. 1998; 93(7):1090-6. doi: 10.1111/j.1572-0241.1998.00335.x
30. Chang FY, Lai KH, Wang TF, Lee SD, Tsai YT, Tsay SH. Location and type of gastric carcinoma in relation to pepsinogen I level in blood. Scandinavian journal of gastroenterology. 1992; 27(10):884-8.
31. Agkoc M, Dursun H, Albayrak F, Yilmaz O, Kiziltunc A, Yilmaz A, et al. Usefulness of serum pepsinogen levels as a screening test for atrophic gastritis and gastric cancer. Eurasian J Med. 2010; 42(1):15-8. doi: 10.5152/eajm.2010.05
32. Aoki K, Misumi J, Kimura T, Zhao W, Xie T. Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen I, II and of PG I/PG II ratios in a gastric cancer case-control study. Journal of epidemiology / Japan Epidemiological Association. 1997; 7(3):143-51.
33. Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H. Evaluation of blood tests to predict normal gastric mucosa. Scandinavian journal of gastroenterology. 2000; 35(8):791-5.
34. He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. Journal of gastroenterology and hepatology. 2011; 26(6):1039-46. doi: 10.1111/j.1440-1746.2011.06692.x
35. Aulia D, Manz GO, Simadibrata M. Pepsinogen I concentration in organic dyspepsia patients at Gastroenterology Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital. Acta Med Indones. 2009; 41(3):107-14.
36. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World journal of gastroenterology: WJG. 2009; 15(7):853-9.
37. Chae H, Lee JH, Lim J, Kim M, Kim Y, Han K, et al. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis]. Korean J Lab Med. 2008; 28(3):201-6. doi: 10.3343/kjlm.2008.28. 3.201
38. Sierra R, Une C, Ramirez V, Gonzalez MI, Ramirez JA, de Mascarel A, et al. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clinical and experimental medicine. 2006; 6(2):72-8. doi: 10.1007/s10238-006-0098-3
39. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia. 2004; 6 (5):449-56. doi: 10.1593/neo.03505
40. Wu KC, Li HT, Qiao TD, Li CN, Ji WS, Tian FQ, et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis. 2004; 5(1):22-7.
41. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F, Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003; 88(8):1239-47. doi: 10.1038/sj.bjc.6600877
42. Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Med J Islam Repub Iran. 2014; 28:150.
43. Kekki M, Samloff IM, Varis K, Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl. 1991; 186:109-16.
44. Nardone G, Rocco A, Staibano S, Mezza E, Autiero G, Compare D, et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther. 2005; 22(11-12):1139-46. doi: 10.1111/j.1365-2036.2005.02734.x
45. Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1998; 7(3):261-3.
46. Sitas F, Smallwood R, Jewell D, Millard PR, Newell DG, Meuwissen SG, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1993; 2(2):119-23.
47. Thakkar H, Davey CL, Medcalf EA, Skingle L, Craig AR, Newman DJ, et al. Stabilization of turbidimetric immunoassay by covalent coupling of antibody to latex particles. Clinical chemistry. 1991; 37(7):1248-
48. Epub 1991/07/01.
49. Huang M, Tang AG, Mu S, Yang JJ, Xiang ZY, Liu B, et al. Serum pepsinogen reference intervals in apparently healthy Chinese population with latex enhanced turbidimetric immunoassay. Journal of clinical pathology. 2014; 67(4):350-4. doi: 10.1136/jclinpath-2013-201942
50. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87-108. doi: 10.3322/caac.21262
51. Huang YK, Yu JC. Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review. World journal of gastroenterology: WJG. 2015; 21(34):9863-86. doi: 10.3748/wjg. v21.i34.9863
52. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer research and treatment: official journal of Korean Cancer Association. 2005; 37(6):325-31. Epub 2005/12/01. doi: 10.4143/crt. 2005.37.6.325
53. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007; 12(1):1-15. doi: 10.1111/j.1523- 5378.2007.00475.x
54. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev. 2001; 10(2):107-12.
55. Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pacific journal of cancer prevention: APJCP. 2014; 15(15):6295-300. Epub 2014/08/16.
56. Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015. doi: 10. 1136/gutjnl-2014-308588
57. Park CH, Kim EH, Jung DH, Chung H, Park JC, Shin SK, et al. The new modified ABCD method for gastric neoplasm screening. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015. doi: 10.1007/s10120-015-0473-4
58. Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011; 141(3):837-45 e1-7. doi: 10.1053/j.gastro.2011.05.040
59. Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC gastroenterology. 2014; 14:74. doi: 10.1186/1471-230X-14-74
60. Syrjanen KJ, Sipponen P, Harkonen M, Peetsalu A, Korpela S. Accuracy of the GastroPanel test in the detection of atrophic gastritis. European journal of gastroenterology & hepatology. 2015; 27(1):102-4. doi: 10.1097/MEG.0000000000000215
61. McNicholl AG, Forne M, Barrio J, De la Coba C, Gonzalez B, Rivera R, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European journal of gastroenterology & hepatology. 2014; 26 (9):941-8. doi: 10.1097/MEG.0000000000000132
62. Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio-a possible novel and noninvasive marker for gastric atrophy. Hepatogastroenterology. 2004; 51(59):1249-54.
63. Sadjadi A, Yazdanbod A, Lee YY, Boreiri M, Samadi F, Alizadeh BZ, et al. Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis. PloS one. 2013; 8 (9):e74440. doi: 10.1371/journal.pone.0074440
64. Penno MA, Klingler-Hoffmann M, Brazzatti JA, Boussioutas A, Putoczki T, Ernst M, et al. 2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. Journal of proteomics. 2012; 77:40-58. doi: 10.1016/j.jprot.2012.07.002
65. Pals G, Rasanen V, Meuwissen SG, Frants RR, Kostense PJ, Eriksson AW. Enzyme-linked immunosorbent assay and radioimmunoassay of serum pepsinogen A. Scand J Clin Lab Invest. 1987; 47 (1):29-33.
66. Yang SK, Xiao L, Zhang H, Xu XX, Song PA, Liu FY, et al. Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: a systematic review and meta-analysis. BMC infectious diseases. 2014; 14:452. Epub 2014/08/26. doi: 10.1186/1471-2334-14-452
67. Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014; 20(2):105-13. doi: 10.1111/1469-0691.12474
68. Lin F, Tan HJ, Guan JS, Lim YP. Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery. Expert review of proteomics. 2014; 11(4):515-30. Epub 2014/04/ 02. doi: 10.1586/14789450.2014.904751